4-amino-5-(4-chlorophenyl)-7-(dimethylethyl) pyrazolo[3,4-d]pyrimidine | 1028313-71-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl) pyrazolo[3,4-d]pyrimidine
• 英文别名: 4-Amino-7-t-butyl-5-(4'-methylphenyl)pyrazolo[3,4-d]pyrimidine；4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d-]pyrimidine；7-tert-butyl-5-(4-methylphenyl)-6H-pyrazolo[3,4-d]pyrimidin-4-amine
• CAS: 1028313-71-4
• 化学式: C₁₆H₂₁N₅
• 分子量: 283.376
• InChiKey: FFRCRTVMLYWAIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  57.2
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Method of treating cancers with SAHA and pemetrexed
  申请人：Pluda James

  公开号：US20070117815A1

  公开（公告）日：2007-05-24

  The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of an anti-cancer agent. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

  本发明涉及一种治疗需要的受试者癌症的方法，通过向需要的受试者施用一定量的组蛋白去乙酰化酶（HDAC）抑制剂或其药用可接受的盐或水合物的第一量，以及一定量的抗癌药物。HDAC抑制剂和抗癌药物可以被施用以包含治疗有效量。在各种方面，HDAC抑制剂和抗癌药物的效果可能是相加的或协同的。
• PTEN PHOSPHORYLATION-DRIVEN RESISTANCE TO CANCER TREATMENT AND ALTERED PATIENT PROGNOSIS
  申请人：Furnari Frank

  公开号：US20120165340A1

  公开（公告）日：2012-06-28

  Indicators that can guide clinical decisions in cancer, particularly posttranslational modification of proteins which result in altered prognosis and differential sensitivity to targeted cancer therapy, are provided. In particular, monitoring of phosphorylation of PTEN may be utilized to predict or assess drug response, drug sensitivity, and clinical outcome. Modulation of PTEN phosphorylation may be utilized to alter sensitivity and outcome in cancer patients. Posttranslational modification of PTEN, particularly phosphorylation, is correlated with resistance to targeted cancer therapy, including EGFR inhibitors, and with reduced survival prognosis. Methods and assays for determining phosphorylation of PTEN, particularly Y240 phosphorylation, are provided. Methods for sensitizing tumors to inhibition and targeted therapy by modulating PTEN phosphorylation are provided.

  提供了可以指导癌症临床决策的指标，特别是蛋白质的后转录修饰，这些修饰会导致预后改变和对靶向癌症治疗的敏感性不同。特别是，监测PTEN的磷酸化可能被用来预测或评估药物反应、药物敏感性和临床结果。调节PTEN的磷酸化可能被用来改变癌症患者的敏感性和结果。PTEN的后转录修饰，特别是磷酸化，与对靶向癌症治疗的抵抗力相关，包括EGFR抑制剂，并且与降低的生存预后相关。提供了确定PTEN磷酸化的方法和检测方法，特别是Y240磷酸化。提供了通过调节PTEN磷酸化来使肿瘤对抑制和靶向治疗更敏感的方法。
• NEW 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO[3,4-D PYRIMIDINE AND PYRROLO[2,3-D]PYRIMIDINE AND USES THEREOF
  申请人：Schenone Silvia

  公开号：US20100249152A1

  公开（公告）日：2010-09-30

  The present invention relates to a compound 4-substituted derivative of pyrazolo[3,4-d]pyrimidine or of pyrrolo[2,3-d]pyrimidine having the formula (I) and uses thereof, in particular for the treatment of bone related diseases and tumours.

  本发明涉及具有以下式(I)的吡唑并[3,4-d]嘧啶或吡咯[2,3-d]嘧啶的化合物4-取代衍生物及其用途，特别是用于骨相关疾病和肿瘤的治疗。
• Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine
  申请人：Barge Alan

  公开号：US20060142297A1

  公开（公告）日：2006-06-29

  The invention concerns a combination comprising an inhibitor of Src kinase and the cytotoxic agent gemcitabine, a pharmaceutical composition comprising such a combination and its use in the treatment or prophylaxis of cancer, particularly of pancreatic cancer.

  本发明涉及一种组合物，包括Src激酶抑制剂和细胞毒素吉西他滨，一种含有该组合物的药物组合物以及其在治疗或预防癌症，特别是胰腺癌方面的用途。
• Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use
  申请人：Curwen Owen Jon

  公开号：US20060223815A1

  公开（公告）日：2006-10-05

  The invention relates to the use of an anti-angiogenic agent in combination with an inhibitor of the Src family of non-receptor tyrosine kinases in the manufacture of a medicament for use in the substantially normotensive treatment in a warm-blooded mammal such as a human being of a disease state associated with angiogenesis, the Src kinase inhibitor being administered in an amount effective to counteract substantially the hypertension induced by the anti-angiogenic agent.

  本发明涉及在制造一种药物时使用抗血管生成剂与Src家族非受体酪氨酸激酶抑制剂相结合，用于治疗与血管生成有关的疾病状态，如在温血哺乳动物（如人类）中进行实质性正常血压治疗。 Src激酶抑制剂的用量有效地对抗抗血管生成剂引起的高血压。